UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------------
FORM 10-Q/A
-------------------------------------
(Mark One)
|X| Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act
of 1934 For the quarterly period ended August 31, 2005.
or
|_| Transition Report Under Section 13 or 15(d) of The Securities Exchange Act
of 1934 For the transition period from ________to__________.
Commission File Number 0-26057
BIOPHAN TECHNOLOGIES, INC.
-----------------------------------------------
(Name of issuer in its charter)
Nevada 82-0507874
----------------------------- ------------------
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
--------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(585) 214-2441
-------------------------
Issuer's telephone number
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act during the past
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.
Yes |X| No |_|
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).
Yes |_| No |X|
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).
Yes |_| No |X|
Explanatory Note
The purpose of this amendment on Form 10-Q/A to our Quarterly Report on
Form 10-Q for the quarterly period ended August 31, 2005 is to file in
unredacted form Exhibit 10.2 (our License Agreement, dated June 30, 2005, with
Boston Scientific Scimed, Inc.), which was originally filed in redacted form
pursuant to a request for confidential treatment. We have withdrawn our request
for confidential treatment. The Items of our Quarterly Report on Form 10-Q for
the quarterly period ended August 31, 2005 which are amended herein are: Item
13. Exhibits and Financial Statement Schedules. Exhibits - Exhibits 10.2, 31.1
and 31.2 are being refiled herewith.
ITEM 13. EXHIBITS
Exhibit No. Exhibit Description Location
10.2 License Agreement dated June 30, 2005 between Filed herewith
Biophan and Boston Scientific Scimed, Inc.
31.1 Certification of C.E.O. pursuant to Filed herewith
Rule 13a-14(a)
31.2 Certification of C.F.O. pursuant to Filed herewith
Rule 13a-14(a)
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
BIOPHAN TECHNOLOGIES, INC.
By: \s\ Robert J. Wood
-------------------------------------
Name: Robert J. Wood
Title: Vice President, Treasurer
and CFO
Dated: January 9, 2006
EXHIBIT INDEX
Exhibit No. Exhibit Description
10.2 License Agreement dated June 30, 2005 between Biophan and Boston
Scientific Scimed, Inc.
31.1 Certification of C.E.O. pursuant to Rule 13a-14(a)
31.2 Certification of C.F.O. pursuant to Rule 13a-14(a)